OssiFi is focused on developing the next generation of bone graft substitutes to stimulate fracture repair, reduce the rate of delayed or non-unions and accelerate return to function. Unlike orthobiologic competitors, OssiFi utilizes a proprietary small molecule to modulate bone growth through Sclerostin inhibition. Its carrier matrix is intended to combine excellent handling characteristics, ideal release kinetics and cellular in-growth capabilities with demonstrated biocompatibility. The company plans to conduct rigorous scientific and clinical studies to prove superior efficacy and safety over standard of care. This evidence, which is lacking in competitive biomaterials, will ultimately drive our commercial success and support the best patient care possible.
View Top Employees from OssiFi IncWebsite | http://www.ossifi.com |
Revenue | $4 million |
Employees | View employees |
Founded | 2011 |
Address | 11235 Mastin, Ste 102, Overland Park, Kansas 66210, US |
Phone | (913) 660-0637 |
Industry | Drug Manufacturing & Research, Health Care, Pharmaceuticals, Medical, Healthcare, Medical Device |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular OssiFi Inc employee's phone or email?
The OssiFi Inc annual revenue was $4 million in 2023.
OssiFi Inc is based in Overland Park, Kansas.
The NAICS codes for OssiFi Inc are [541714, 541, 54, 5417, 54171].
The SIC codes for OssiFi Inc are [87, 873].